Park Joo Hyun, Yang Chul Woo, Kim Young Soo, Lee Seung Hun, Choi Yeong Jin, Kim Yong Soo, Moon In Sung, Koh Yong Bok, Bang Byung Kee
Department of Internal Medicine, Catholic University of Medical College, Seoul, Korea.
Clin Transplant. 2002;16 Suppl 8:18-23. doi: 10.1034/j.1399-0012.16.s8.4.x.
The functional recovery state of renal transplants can be divided into three types: immediate graft function (IGF), slow graft function (SGF) and delayed graft function (DGF). In contrast to the well-known clinical outcomes for IGF and DGF, the pathological findings and clinical outcomes of SGF are undetermined. This study evaluated possible clinicopathological correlations in 237 patients with SGF compared with patients with IGF. IGF and SGF were defined by serum creatinine levels (IGF < 1.2 mg/day l; SGF: >/=1.2 mg/dL) at day 14 after renal transplantation. Graft biopsy was performed on this day, and pathological classification was performed using the Banff schema. The SGF group of patients (n = 121) showed higher rates of cadaver donors and male recipients than the IGF group (n = 116), but there were no significant differences in recipient or donor age, numbers of HLA mismatches, types of immunosuppressant or follow-up periods between two groups. The SGF group showed higher serum creatinine levels at discharge, and a higher incidence of acute rejection than the IGF group (24.8% vs. 8.6%, P < 0.05) and lower graft survival rates (1 year, 93.3% vs. 100%; 5 years, 85.4% vs. 98.6%, respectively; P < 0.05). The presence of acute rejection in the SGF patients indicated a significantly decreased 5-year survival rate compared with the IGF group. The SGF group of patients with borderline pathology had a higher incidence of acute rejection than the IGF group, and significant increases in the expression of mRNA for pro-apoptotic genes (Fas-ligand, granzyme B and perforin) compared with the IGF group. In conclusion, SGF represents the activated immune state and is associated with poor graft outcome. Anti-rejection treatment or modified immunosuppressive regimen may thus be indicated for patients with SGF.
即刻移植肾功能(IGF)、缓慢移植肾功能(SGF)和延迟移植肾功能(DGF)。与IGF和DGF已知的临床结局不同,SGF的病理表现和临床结局尚不确定。本研究评估了237例SGF患者与IGF患者可能存在的临床病理相关性。IGF和SGF通过肾移植后第14天的血清肌酐水平来定义(IGF<1.2mg/日升;SGF:≥1.2mg/dL)。在这一天进行移植肾活检,并使用班夫标准进行病理分类。SGF组患者(n = 121)中尸体供体和男性受者的比例高于IGF组(n = 116),但两组在受者或供者年龄、HLA错配数、免疫抑制剂类型或随访时间方面无显著差异。SGF组出院时血清肌酐水平较高,急性排斥反应发生率高于IGF组(24.8%对8.6%,P<0.05),移植肾存活率较低(1年时分别为93.3%对100%;5年时分别为85.4%对98.6%,P<0.05)。SGF患者发生急性排斥反应表明其5年生存率与IGF组相比显著降低。病理表现为临界状态的SGF组患者急性排斥反应发生率高于IGF组,与IGF组相比,促凋亡基因(Fas配体、颗粒酶B和穿孔素)的mRNA表达显著增加。总之,SGF代表激活的免疫状态,与移植肾不良结局相关。因此,对于SGF患者可能需要进行抗排斥治疗或调整免疫抑制方案。